Screening for inhibitors of allergen-associated airway smooth muscle contraction

筛选过敏原相关气道平滑肌收缩抑制剂

基本信息

批准号：
10176398
负责人：
RAMASWAMY KRISHNAN
金额：
$ 21.88万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10176398
关键词：
Adrenal Cortex Hormones Affinity AlamarBlue Allergens Allergic inflammation Animals Antifungal Agents Aspergillus fumigatus Asthma Biological Assay Biological Sciences Bronchoconstriction Bronchodilator Agents Cell Survival Cytoskeleton Data Dinoprostone Disease Dose Evaluation Extracellular Matrix Focal Adhesions Gene Expression Generations Human Hypersensitivity IgE Inflammatory Inhalation Lead Life Lung Measurement Mediating Mediator of activation protein Molds Mucous Membrane Mus Muscle Contraction Mycoses N-Cadherin Patients Peptide Hydrolases Production Safety Scheme Serine Protease Serine Proteinase Inhibitors Signal Pathway Slice Smooth Muscle Myocytes Stress Fibers Submucosa Symptoms Testing Therapeutic Toxic effect Validation aggressive therapy airway hyperresponsiveness alkalinity anti-IgE asthmatic asthmatic airway smooth muscle asthmatic patient attenuation base comparative constriction cytokine cytotoxicity design drug candidate druggable target experience follow-up fungus high throughput screening in vivo inhibitor/antagonist insight novel omalizumab precision medicine protein expression public health relevance respiratory smooth muscle screening small molecular inhibitor small molecule inhibitor therapeutic target

项目摘要

PROJECT SUMMARY Despite aggressive treatment with high-dose inhaled corticosteroids plus bronchodilators, approximately 5-10% of people with asthma (15-30 million) experience severe and life-threatening symptoms of bronchoconstriction. Nearly one-half of these severe asthma patients are also “sensitized” (i.e. have IgE mediated allergy) to common molds such as Aspergillus fumigatus (Af). This condition has now been recognized as a distinct entity and designated fungal asthma (FA). Unfortunately, current therapies for FA—antifungals and/or omalizumab (anti- IgE)—have not proven to be efficacious in the long-term. By studying Af-induced bronchoconstriction in mice and people with asthma, our team has discovered a novel, direct, and druggable target in FA—the Af allergen-derived serine protease, alkaline protease 1 (Alp1). Alp1 promotes the defining symptom of FA—bronchoconstriction—by inducing airway smooth muscle (ASM) contraction, through mechanisms that appear to be independent of allergic inflammation. In this application, we will pursue the hypothesis that inhibitors of Alp1-induced human ASM contraction can be discovered by high throughput screening (HTS). In aim 1, we will use HTS to identify small molecular inhibitors of Alp1 protease. In aim 2, we will examine the effects of FA pathobiology on the efficacy of Alp1-inhibitor therapy. In aim 3, we will determine mechanism and examine significance for Alp1-inhibitor therapy. We expect our approach to identify novel anti-FA drug candidates, and in doing so, offer substantial insight into both ASM-intrinsic and allergen protease dependent mechanisms of bronchoconstriction.

项目概要尽管使用大剂量吸入皮质类固醇加支气管扩张剂进行积极治疗，但仍有约 5-10% 的哮喘患者（15-3000 万）经历严重且危及生命的支气管收缩症状。这些严重哮喘患者中近一半也对常见物质“敏感”（即 IgE 介导的过敏）。霉菌，如烟曲霉 (Af)，这种情况现已被认为是一种独特的实体，并且不幸的是，目前针对 FA 的治疗方法是抗真菌药物和/或奥马珠单抗（抗真菌药物）。 IgE）——尚未证明长期有效。通过研究房颤引起的小鼠和哮喘患者的支气管收缩，我们的团队发现了一种新的， FA 中的直接且可药物化的靶点——Af 过敏原衍生的丝氨酸蛋白酶、碱性蛋白酶 1 (Alp1)。通过诱导气道平滑肌 (ASM) 促进 FA 的典型症状——支气管收缩收缩，通过似乎独立于过敏性炎症的机制。将追求这样的假设：Alp1 诱导的人类 ASM 收缩的抑制剂可以通过高在目标 1 中，我们将使用 HTS 来鉴定 Alp1 蛋白酶的小分子抑制剂。目标 2，我们将研究 FA 病理学对 Alp1 抑制剂治疗疗效的影响。确定 Alp1 抑制剂治疗的机制并检查其意义。新型抗 FA 候选药物，从而提供对 ASM 内在和过敏原的深入了解支气管收缩的蛋白酶依赖性机制。

项目成果

期刊论文数量（3）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

CD38 plays an age-related role in cholinergic deregulation of airway smooth muscle contractility.

CD38 在气道平滑肌收缩力的胆碱能失调中发挥与年龄相关的作用。

DOI：
发表时间：
2022-05
期刊：
影响因子：
0
作者：
Bai, Yan;Guedes, Alonso G P;Krishnan, Ramaswamy;Ai, Xingbin
通讯作者：
Ai, Xingbin

Aspergillus fumigatus Protease Alkaline Protease 1 (Alp1): A New Therapeutic Target for Fungal Asthma.

烟曲霉蛋白酶碱性蛋白酶 1 (Alp1)：真菌性哮喘的新治疗靶点。

DOI：
发表时间：
2020-06-16
期刊：
影响因子：
0
作者：
Druey, Kirk M;McCullough, Morgan;Krishnan, Ramaswamy
通讯作者：
Krishnan, Ramaswamy

Multiscale stiffness of human emphysematous precision cut lung slices.

人肺气肿精密切割肺切片的多尺度硬度。

DOI：
发表时间：
2023-05-19
期刊：
影响因子：
13.6
作者：
Kim, Jae Hun;Schaible, Niccole;Hall, Joseph K;Bartolák;Deng, Yuqing;Herrmann, Jacob;Sonnenberg, Adam;Behrsing, Holger P;Lutchen, Kenneth R;Krishnan, Ramaswamy;Suki, Béla
通讯作者：
Suki, Béla